Dashboard/LOTUSEYE

LOTUSEYE

OVERVALUED

Lotus Eye Hospital and Institute Limited

Healthcare · NSE

↓ 808.3% vs fair value

52W Low

₹63

+60.9% from low

52W High

₹147

-30.6% from high

News sentiment (0 articles)

0 bull0 neutral0 bear

✦

Analyst Note

2d ago

Lotus Eye Hospital trades at ₹102, significantly overvalued relative to its fair value of ₹11.23, with a massive -816.6% margin of safety and low confidence in valuation metrics. The stock struggles with negative free cash flow of -₹2 Cr, deteriorating ROCE at 2.8%, and five-year earnings decline of -37.2%, though revenue grew 10.6% annually. A PE ratio of 320.3x and Piotroski score of just 5 signal poor financial health marked by paper profits rather than genuine earnings. This suits only high-risk investors comfortable with distressed healthcare plays pending operational turnaround.

Valuation Gauge

OVERVALUED-808.3% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹102

Fair Value

₹11

Fair Value Analysis

₹11

Based on balance sheet strength analysis and earnings growth potential for Healthcare sector companies | CAUTION: ROCE declining (latest 5.6%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 1.0% (ROE 0.9%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.

Low confidence

Balance Sheet Value

33% weight

₹21

Growth Valuation

67% weight

₹6

Price vs Market

LOTUSEYE

Nifty 50

Shareholding Pattern

Stock Health Score

Weak Fundamentals

3.7 / 10

Profitability

6/10

ROE of 0.9% is below the Healthcare sector benchmark of 15%

Debt & Leverage

10/10

D/E ratio of 0.1x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

1/10

P/E of 381.3x is 2.4x the Healthcare sector median of 160x — expensive

Cash Flow

1/10

Negative FCF of ₹-2 Cr — company is consuming more cash than it generates

Earnings Growth

1/10

5yr EPS CAGR of -37.2% — severe earnings decline

Dividend

4/10

No dividend — typical for growth-stage companies

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

-1.7%

Free cash flow / market cap

Revenue Growth (YoY)

-15.6%

Year-on-year revenue change

Profit Growth (YoY)

-96.8%

Year-on-year PAT change

Operating Cash Flow

₹3 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹0.3

P/E Ratio

381.3x

P/B Ratio

3.4x

ROE

0.9%

ROCE

2.8%

Debt / Equity

0.08x

Beta

0.57

Div Yield

—

FCF (Cr)

₹-2 Cr

Revenue (Cr)

₹49 Cr

EPS Growth 5Y

-37.2%

Mkt Cap (Cr)

₹213 Cr

52W High

₹147

52W Low

₹63.4

Book Value/Share

₹30.3

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹52 Cr	₹3 Cr	5.3%	₹1 Cr	₹0.31
2025-03-31	₹50 Cr	₹4 Cr	7.2%	₹1 Cr	₹0.36
2024-03-31	₹48 Cr	₹7 Cr	13.8%	₹3 Cr	₹1.40
2023-03-31	₹47 Cr	₹8 Cr	16.3%	₹4 Cr	₹1.96
2022-03-31	₹39 Cr	₹6 Cr	15.2%	₹3 Cr	₹1.43
2021-03-31	₹32 Cr	₹4 Cr	11.2%	₹2 Cr	₹0.75
2020-03-31	₹41 Cr	₹4 Cr	9.8%	₹1 Cr	₹0.51
2019-03-31	₹38 Cr	₹3 Cr	8.4%	₹1 Cr	₹0.34
2018-03-31	₹38 Cr	₹4 Cr	11.4%	₹2 Cr	₹0.84
2017-03-31	₹34 Cr	₹3 Cr	9.8%	₹0 Cr	₹0.21
2016-03-31	₹31 Cr	₹4 Cr	12.8%	₹0 Cr	₹0.05
2015-03-31	₹30 Cr	₹2 Cr	7.3%	₹-2 Cr	₹-0.95
2014-03-31	₹29 Cr	₹3 Cr	11.5%	₹0 Cr	₹0.02

Compounded Growth Rates

Sales Growth

3Y+3.2%

5Y+9.8%

10Y+5.2%

Profit Growth

3Y-45.8%

5Y-16.2%

10Y+20.6%

EPS Growth

3Y-45.9%

5Y-16.2%

10Y+20.0%

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
ALPA Alpa Laboratories Limited	₹62.1	₹198.5	+68.7%	9.4	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹670	₹1,585.8	+57.8%	103.2	7.9%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹300	₹592.5	+49.4%	7.1	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹147.6	₹281.2	+47.5%	19.5	1.9%	FAIRLY_VALUED
VIMTALABS Vimta Labs Limited	₹414.8	₹722.6	+42.6%	24.6	16.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹38.4	₹52.8	+27.2%	21	10.8%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹410	₹462.6	+11.4%	20	20.6%	FAIRLY_VALUED
KRONOX Kronox Lab Sciences Limited	₹133	₹130.7	-1.8%	16.9	24.8%	FAIRLY_VALUED